about
BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations.AR Signaling in Human Malignancies: Prostate Cancer and Beyond.Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities.Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification.Recent Advances in Prostate Cancer Treatment and Drug Discovery.PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer.A novel molecular mechanism for a long non-coding RNA PCAT92 implicated in prostate cancer
P2860
Q47651456-25706642-83DE-4F3E-AB0F-7A90D8EAF626Q48218659-D671CD54-BEA3-4E27-9247-62501B2CACF2Q52566012-104C9E5E-EE75-4A1E-8445-97C608B141A5Q52629153-17706445-448D-401F-AA26-5C6408472555Q54111821-3940DA46-69BB-4EA4-A474-3E30B8736198Q54984581-B10B99DA-0679-4A5D-88FD-62E05D9497F9Q58727464-94653D30-0E55-418E-883D-FC462A649F43
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
AR Signaling and the PI3K Pathway in Prostate Cancer
@en
AR Signaling and the PI3K Pathway in Prostate Cancer.
@nl
type
label
AR Signaling and the PI3K Pathway in Prostate Cancer
@en
AR Signaling and the PI3K Pathway in Prostate Cancer.
@nl
prefLabel
AR Signaling and the PI3K Pathway in Prostate Cancer
@en
AR Signaling and the PI3K Pathway in Prostate Cancer.
@nl
P2860
P356
P1433
P1476
AR Signaling and the PI3K Pathway in Prostate Cancer
@en
P2093
Leila Khoja
P2860
P356
10.3390/CANCERS9040034
P577
2017-04-15T00:00:00Z